364 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (364)
- Addiction (2)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (2)
- Blood Disorders (1)
- Bone & Muscle (2)
- Cancer (109)
- Child Development (1)
- COVID-19 (Coronavirus) (10)
- Diabetes (9)
- Ear, Nose and Throat (6)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (3)
- Hair and Skin Disorders (1)
- Healthy Volunteers (44)
- Heart Disease (25)
- Infectious Disease (11)
- Liver Disease (14)
- Lung Disease (3)
- Neurological Disorders (45)
- Nutrition (1)
- Obesity (8)
- Obstetrics & Gynecology (12)
- Pediatrics (26)
- Psychiatric Disorders (8)
- Rehabilitation (1)
- Stroke (2)
- Transplant (15)
Displaying 1 - 21 of 21
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of…
Condition: Heart Disease / Valve Disease
Investigator: Susheel Kodali, MD
Status: Currently Recruiting
This is designed for patients with severe, symptomatic mitral regurgitation who are not candidates for conventional mitral repair.
Condition: Valve Disease / Tricuspid Valve Disease
Investigator: Susheel Kodali, MD
Status: Currently Recruiting
The Edwards Cardioband Tricuspid Valve Reconstruction FIT valve repair system is a prospective, single arm, multi-center study to evaluate the safety and performance of the Cardioband Tricuspid System. The Edwards Cardioband Tricuspid Valve Reconstruction System is intended for patients with tricuspid regurgitation deemed to be potential candidates for…
Condition: Valve Disease / Aortic Valve Disease
Investigator: Torsten Vahl, MD
Status: Currently Recruiting
The objective of the study is to evaluate the safety and efficacy of the JenaValve Pericardial TAVR system when treating patients with aortic regurgitation. Aortic Regurgitation is a condition that develops when the heart's aortic valve does close tightly, therefore the blood leaks back into the heart chamber. The JenaValve Pericardial TAVR system will…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual treatment alone to using duvelisib or CC-486 plus the usual treatment for patients with peripheral T-cell lymphoma. The usual approach for patients who are not in a study is treatment with the FDA-approved chemotherapy regimens used in this trial (CHOP or CHOEP) without the addition of the study drugs…
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1)…
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
Can we lower the chance of Diffuse Large B-cell Lymphoma (DLBCL) cancer growing or spreading by adding treatment to the usual therapy? This study is being done to find out if this approach is better or worse than the usual approach for DLBCL patients receiving chimeric antigen receptor (CAR) T-cell therapy. The usual approach for Relapsed/Refractory DLBCL…
Condition: Valve Disease / Mitral Valve Disease
Investigator: Isaac George, MD
Status: Currently Recruiting
This is a prospective multicenter study whose purpose is to establish the safety and effectiveness of the Edwards SAPIEN 3 and SAPIEN 3 Ultra valves with Commander delivery system in patients with severe symptomatic calcific mitral valve disease with severe mitral annular calcification (which is a progressive loss of function of the mitral valve due to…
Condition: Cancer / Lymphoma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm),…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to see what effects, good and/or bad, the study drug, ST-001, has on you and your cancer, to find the best dose for treating your condition, and to see how safe ST-001 is for participants with your condition. This study will help us understand more about whether intravenous (injected into the vein) ST-001, will be a useful study…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
This study is being done to determine if a study drug called lenalidomide can be combined with full doses of EPOCH chemotherapy for patients with Adult T-Cell Leukemia-Lymphoma (ATLL), and to define the highest dose and longest duration of lenalidomide that can be given safely in combination with EPOCH. EPOCH chemotherapy is a combination of five…
Condition: Valve Disease / Mitral Valve Disease
Investigator: Susheel Kodali, MD
Status: Currently Recruiting
The study is designed to compare the safety and effectiveness of the PASCAL System to the MitraClip System for reduction of degenerative mitral regurgitation.
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will utilize an investigational drug combination (also known as the study drugs) called relatlimab and nivolumab as a possible treatment for recurrent/relapsed (returned) or refractory (treatment-resistant) cHL and NHL. An investigational drug combination is one that has not been approved by regulatory agencies, such as the United States (US)…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to find out the safety, effectiveness, and blood levels of various doses of the study drug in participants with T-cell lymphoma that has not improved or has gotten worse. ONO-4685 is an experimental drug which is not approved by Health Authorities including the United States Food and Drug Administration (FDA). The study drug is…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental products, KITE-363 and KITE-753, are safe and effective in treating relapsed and/or refractory B-cell lymphoma. Participants will receive either KITE-363 or KITE-753 one time through intravenous (IV) infusion. The experimental treatment would involve removing some of your immune cells, genetically…
Condition: Valve Disease / Mitral Valve Disease
Investigator: Susheel Kodali, MD
Status: Currently Recruiting
This is a randomized controlled trial (RCT) that will compare the clinical outcome of MitraClip device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team. In this trial,…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy (chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA EPOCH R (dose-adjusted etoposide, prednisone, vincristine,…
Condition: Valve Disease / Tricuspid Valve Disease
Investigator: Susheel Kodali, MD
Status: Currently Recruiting
The goal of this early feasibility study is to gain initial insight into the basic safety and performance of transluminal (through the blood vessels) implantation of the PASCAL System's implant (composed of man-made materials). We are trying to evaluate the safety and performance of the PASCAL System with Optimal Medical Therapy (OMT) (also known as…
TTVR Early Feasibility Study in Patients with Symptomatic Severe Tricuspid Regurgitation - Medtronic
Condition: Valve Disease / Tricuspid Valve Disease
Investigator: Susheel Kodali, MD
Status: Currently Recruiting
This is a research study for patients who have Tricuspid Regurgitation (TR), a condition that occurs when the three leaflets of the heart's tricuspid valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart has to pump more blood with each beat to push the same amount of blood…
Condition: Valve Disease / Aortic Valve Disease
Investigator: Tamim Nazif, MD
Status: Currently Recruiting
This prospective, multicenter trial is looking at the investigative device called the ACURATE Transcatheter Aortic Valve System for TAVR to see if it is safe and effective in treating patients with severe symptomatic native aortic stenosis. The ACURATE Transcatheter Aortic Valve System for TAVR is designed for iliofemoral access and delivery of a self-…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE